Delavirdine
(重定向自Rescriptor)


![Delavirdine synthesis:[3][4]](/uploads/202502/07/Delavirdine_synthesis5825.png)
Delavirdine (DLV) (brand name Rescriptor) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by ViiV Healthcare. It is used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1. It is presented as the mesylate. The recommended dosage is 400 mg, three times a day.